ANI Pharma (ANIP) Tops Q1 EPS by 33c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- US futures fall on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
ANI Pharmaceuticals Reports First Quarter 2021 Results
May 7, 2021 6:50 AM EDT-- First quarter 2021 net revenues of $54.5 million; net income of $0.1 million and diluted earnings per share of $0.01 --
-- First quarter adjusted non-GAAP EBITDA of $18.9 million and adjusted non-GAAP diluted earnings per share of $1.04 --
-- Cortrophin® Gel sNDA re-filing on track for Q2 2021 submission --
-- Strengthened R&D engine and enhanced generics and CDMO business through pending acquisition of Novitium Pharma--
-- Expanded branded products portfolio through April 1 acquisition of Sandoz Inc. NDAs --
... More